Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 14, 2016 - Issue 2
Submit an article Journal homepage
2,598
Views
29
CrossRef citations to date
0
Altmetric
Reviews

Dosing of antifungal agents in obese people

Kenna D. PaynePharmacy Practice, Texas Tech University Health Sciences Center, Amarillo, TX, USA
&
Ronald G. HallPharmacy Practice, Texas Tech University Health Sciences Center, Dallas, TX, USACorrespondence[email protected]
Pages 257-267 | Received 10 Aug 2015, Accepted 03 Dec 2015, Published online: 28 Dec 2015

References

  • Papers of special note have been highlighted as:
  • • of interest
  • •• of considerable interest
  • Flegal KM, Carroll, MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303:235–241.
  • Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384:766–781.

• This article describes the global nature of the obesity pandemic.

  • Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63:2985–3023.
  • Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20:133–163.
  • Diekema D, Arbefeville S, Boyken L, et al. The changing epidemiology of healthcare-associated candidemia over three decades. Diagn Microbiol Infect Dis. 2012;73:45–48.
  • Padawer D, Pastukh N, Nitzan O, et al. Catheter-associated candiduria: Risk factors, medical interventions, and antifungal susceptibility. Am J Infect Control. 2015;43:e19–22.
  • Kett DH, Shorr AF, Reboli AC, et al. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis. Crit Care. 2011;15:R253.
  • Wang JF, Xue Y, Zhu XB, et al. Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs. Eur J Clin Microbiol Infect Dis. 2015;34:651–659.
  • Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45:883–893.
  • Payne KD, Hall RG 2nd. Dosing of antimbacterial agents in obese adults: does one size fit all? Expert Rev Anti Infect Ther. 2014;12:829–854.
  • Graninger W, Presteril E, Schneeweiss B, et al. Treatment of Candida albicans fungaemia with fluconazole. J Infect. 1993;26:133–146.
  • Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother. 2007;51:35–39.

• This article demonstrates the relationship between dose/MIC24 ratio and mortality.

  • Garey KW, Pai MP, Suda KJ, et al. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf. 2007;16:919–927.

•• This article demonstrates that increased patient weight is an independent risk factor for inadequate fluconazole dosing, as described by the IDSA guidelines.

  • Cohen LG, DiBiasio A, Lisco SJ, et al. Fluconazole serum concentrations and pharmacokinetics in an obese patient. Pharmacotherapy. 1997;17:1023–1026.
  • Lopez ND, Phillips KM. Fluconazole pharmacokinetics in a morbidly obese, critically ill patient receiving continuous venovenous hemofiltration. Pharmacotherapy. 2014;34:e162–168.
  • Bergner R, Hoffmann M, Riedel KD, et al. Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg. Nephrol Dial Transplant. 2006;21:1019–1023.
  • Gaskell KM, Rothe C, Gnanadurai R, et al. A prospective study of mortality from cryptococcal meningitis following treatment induction with 1200 mg oral fluconazole in Blantyre, Malawi. PLoS One. 2014;9:e110285.
  • Hardin TC, Graybill JR, Fetchick R, et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother. 1988;32:1310–1313.
  • Lee DG, Chae H, Yim DS, et al. Population pharmacokinetics of intravenous itraconazole in patients with persistent neutropenic fever. J Clin Pharm Ther. 2009;34:337–344.
  • Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53:24–34.
  • Pai MP, Lodise TP. Steady-state plasma pharmacokinetics of oral voriconazole in obese adults. Antimicrob Agents Chemother. 2011;55:2601–2605.

•• This study observed similar pharmacokinetics for voriconazole in both obese and nonobese adults.

  • Friberg L, Ravva P, Karlsson MO, et al. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother. 2012;56:3032–3042.
  • Koselke E, Kraft S, Smith J, et al. Evaluation of the effect of obesity on voriconazole serum concentrations. J Antimicrob Chemother. 2012;67:2957–2962.
  • Davies-Vorbrodt SIJ, Tegtmeier BR, Dadwal SS, et al. Voriconazole serum concentrations in obese and overweight immunocompromised patients. Pharmacotherapy. 2013;33:22–30.
  • Liu P, Mould DR. Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis. Antimicrob Agents Chemother. 2014;58:4718–4726.
  • Dolton MJ, Mikus G, Weiss J, et al. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. J Antimicrob Chemother. 2014;69:1633–1641.
  • ClinicalTrials.gov. National Library of Medicine. Bethesda (MD): 2000–2015. [cited 2015 Dec 1]. Available from: https://clinicaltrials.gov.
  • Krishna G, AbuTarif M, Xuan F, et al. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy. 2008;28:1223–1232.
  • Kohl V, Muller C, Cornely OA, et al. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother. 2010;54:207–212.

• This population pharmacokinetic analysis did not find weight to be significantly associated with posaconazole pharmacokinetics.

  • Vehreschild JJ, Muller C, Farowski F, et al. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur J Clin Pharmacol. 2012;68:987–995.
  • Kersemaekers WM, Van Iersel T, Nassander U, et al. Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects. Antimicrob Agents Chemother. 2015;59:1246–1251.
  • Miceli MH, Perissinotti AJ, Kauffman CA, et al. Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhea: single centre retrospective analysis. Mycoses. 2015;58:432–436.
  • European Medicines Agency. Noxafil-H-C-610-X-0033: EPAR-Assessment Report-Variation [Internet]. 2014. [cited 2015 Nov]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000610/WC500181840.pdf
  • Dolton MJ, Ray JE, Marriott D, et al. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother. 2012;56(6):2806–2813.
  • Schmitt-Hoffmann A, Roos B, Maares J, et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006;50:286–293.
  • Cornley OA, Bohme A, Schmitt-Hoffmann A, et al. Safety and pharmacokinetics of isvuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrob Agents Chemother. 2015;59:2078–2085.
  • Wurthwein G, Young C, Lanvers-Kaminsky C, et al. Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother. 2012;56:536–543.
  • Hope WW, Goodwin J, Felton TW, et al. Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens. Antimicrob Agents Chemother. 2012;56:5303–5308.
  • Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother. 2001;45:3487–3496.
  • Vadiei K, Lopez-Berestein G, Luke DR. Disposition and toxicity of amphotericin-B in the hyperlipidemic Zucker rat model. Int J Obes. 1990;14:465–472.
  • Koldin MH, Kobayashi GS, Brajtburg J, et al. Effects of elevation of serum cholesterol and administration of amphotericin B complexed to lipoproteins on amphotericin B-induced toxicity in rabbits. Antimicrob Agents Chemother. 1985;28:144–145.
  • Ramaswamy M, Peteherych KD, Kennedy AL, et al. Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities. Antimicrob Agents Chemother. 2001;45:1184–1191.
  • Groll AH, Mickiene D, Piscitelli SC, et al. Distribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits. Antimicrob Agents Chemother. 2000;44:408–410.
  • Gumbo T, Hiemenz J, Ma L, et al. Population pharmacokinetics of micafungin in adult patients. Diagn Microbiol Infect Dis. 2008;60:329–331.
  • Zomp A, Bookstaver PB, Ahmed Y, et al. Micafungin therapy in a critically ill, morbidly obese patient. J Antimicrob Chemother. 2011;66:2678–2680.
  • Hall RG, Swancutt MA, Gumbo T. Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people. Antimicrob Agents Chemother. 2011;55:5107–5112.
  • Pasipanodya J, Hall R 2nd, Gumbo T. In silico-derived bedside formula for individualized micafungin dosing for obese patients in the age of deterministic chaos. Clin Pharmacol Ther. 2015;97:292–297.

•• This study used pharmacokinetic data from normal weight, overweight, and obese adults receiving micafungin to determine a dosing formula that could be used to maximize the percentage of patients who reach the micafungin AUC/MIC threshold associated with improved clinical outcomes.

  • Sirohi B, Powles RL, Chopra R, et al. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;38:47–51.
  • Nguyen TH, Hoppe-Tichy T, Geiss HK, et al. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother. 2007;60:100–106.
  • Ryan DM, Lupinacci RJ, Kartsonis NA. Efficacy and safety of caspofungin in obese patients. Med Mycol. 2011;49:748–754.
  • Hall RG 2nd, Swancutt MA, Meek C, et al. Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths. Antimicrob Agents Chemother. 2013;57:2259–2264.

• This study demonstrated that weight, not body mass index, is significantly associated with caspofungin pharmacokinetics. Heavier people will likely need increased doses of caspofungin to achieve clinical effectiveness similar to that of nonobese people.

  • Wurthwein G, Cornely OA, Trame MN, et al. Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis. Antimicrob Agents Chemother. 2013;57:1664–1671.
  • Betts RF, Nucci M, Talwar D, et al. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis. 2009;48:1676–1684.
  • Cornely OA, Vehreschild JJ, Vehreschild MJ, et al. Phase II dose escalation study of caspofungin for invasive Aspergillosis. Antimicrob Agents Chemother. 2011;55:5798–5803.
  • Liu P. Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections. Antimicrob Agents Chemother. 2013;57:466–474.
  • Liu P, Ruhnke M, Meersseman W, et al. Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasis. Antimicrob Agents Chemother. 2013;57:1672–1676.
  • Bruggemann RJ, Van Der Velden WJ, Knibbe CA, et al. A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients. J Antimicrob Chemother. 2015;70:1166–1174.
  • Gillum JG, Johnson M, Lavoie S, et al. Flucytosine dosing in an obese patient with extrameningeal cyrptococcal infection. Pharmacotherapy. 1995;15:251–253.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.